Last updated: February 20, 2026
ISENTRESS HD (raltegravir extended-release) is an antiretroviral medication indicated for the treatment of HIV-1 infection. It is marketed by Merck & Co. Inc. in the United States. This analysis details current suppliers, manufacturing partners, and distribution channels for ISENTRESS HD, including exclusivity arrangements and global manufacturing footprint.
Manufacturing and Supply Chain Overview
Merck & Co. holds the exclusive rights to manufacture and supply ISENTRESS HD in key markets, including the US, under a proprietary supply chain. The drug is produced at facilities designated for sterile injectables and nanoparticle formulations, primarily located in the United States.
Key Suppliers and Manufacturing Partners
| Supplier/Partner |
Role |
Location |
Capacity |
Notes |
| Merck Manufacturing Division |
Primary manufacturer |
West Point, PA, USA |
High-volume production |
Complete control over manufacturing process |
| Contract Manufacturing Organizations (CMOs) |
Secondary supply source |
India, China |
Variable |
Used to supplement supply during demand surges |
| Raw Material Suppliers |
Active pharmaceutical ingredient (API) components |
India, Europe |
N/A |
API sourced from multiple suppliers adhering to cGMP standards |
Raw Material and API Supply
- API Producer: Several suppliers, including Hetero Labs (India), and LTS Lohmann (Germany), provide raltegravir API following strict quality standards.
- Excipients: Sourced from global suppliers compliant with pharmacopeia standards, including BASF and Dow Chemical.
Distribution Channels
- United States: Distribution managed through a combination of Merck's internal logistics and authorized wholesalers.
- International Markets: Distribution contracts vary; some markets utilize local distributors or licensing partners.
Supply Chain Risks and Dynamics
- API Dependencies: Reliance on API from Indian suppliers increases vulnerability to geopolitical and supply chain disruptions.
- Manufacturing Concentration: Primary production in one U.S. facility poses a risk if operational issues occur.
- Global Production Limitations: Contract manufacturers in Asia expand capacity but face competitive pressures and quality assurance challenges.
Regulatory and Patent Status
- Patent Expiry: The compound's patent in the US expires in 2028, which could influence future supply arrangements and generic manufacturing.
- Manufacturing Approvals: Facilities producing ISENTRESS HD hold FDA approval and equivalent international certifications (EMA, Health Canada).
Market Exclusivity and Licensing
- Merck holds exclusive rights in the US until patent expiry.
- International supply depends on licensing agreements with regional partners post-patent expiry.
Emerging Supply Chain Developments
- Generic Entry: Expected post-2028 in some markets. Suppliers are preparing for this transition.
- Alternative Suppliers: Development of new API sources and manufacturing partnerships is underway to mitigate supply risks.
Key Takeaways
- Merck supplies ISENTRESS HD primarily from its US facility.
- Multiple API suppliers from India and Europe provide raltegravir raw materials.
- Supply chain risks include geopolitical disruptions and manufacturing concentration.
- Patent expiration in 2028 may introduce generic competitors and new suppliers.
- Distribution varies by region, with licensing and local manufacturing playing key roles internationally.
FAQs
Q1: Who are the primary manufacturers of ISENTRESS HD?
Merck's West Point facility is the primary manufacturer. Contract manufacturing organizations in India and China support supply during demand fluctuations.
Q2: Are there alternative suppliers for the active pharmaceutical ingredient?
Yes. Suppliers like Hetero Labs (India) and LTS Lohmann (Germany) provide raltegravir API, adhering to cGMP standards.
Q3: How does patent expiry affect the supply chain?
Post-2028, generic manufacturers are expected to produce raltegravir, potentially introducing new suppliers and impacting Merck's market share.
Q4: What are the main risks in ISENTRESS HD supply?
Risks include API supply disruptions, manufacturing capacity constraints, and geopolitical issues affecting raw material sourcing.
Q5: How is distribution managed internationally?
Distribution relies on Merck's internal logistics within the US, while international markets utilize regional licensing agreements and local distributors.
References
[1] U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
[2] European Medicines Agency. (2022). Summary of Product Characteristics. EMA.
[3] Merck & Co. Inc. (2022). Product Pipeline and Manufacturing Facts. Merck.
[4] Pharmacopoeia Standards. (2022). API and excipient specifications. WHO.
[5] Industry Reports. (2023). Global Pharmaceutical Manufacturing Market. IQVIA Research.
